| Name | Title | Contact Details |
|---|
Trivani is a Springville, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Charlotte`s Web wasn`t started as a company, it started as a mission to create a world where good health is attainable for all. The Charlotte`s Web extract was something we gave away to people who could benefit from it, a few at first and then many. We labor every day to make this dream a reality and dedicate all our efforts to making the most trustworthy and dependable hemp products. From our seeds, soil, and hands-on approach to farming, to our own FDA registered manufacturing facilities, our rigorous standards for quality and consistency set Charlotte`s Web products apart. That`s why we are the leader in the industry in product quality, safety, and consistency. Our high-quality hemp extract harnesses powerful botanical benefits. Our field is the science of botanics and unlocking their power is our focus. To that end, our mission remains at the core of everything we do: improve lives, naturally.
Savoy Associates is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
Physical Rehabilitation Network (PRN) was founded in 1991 to assist physical therapists in developing and operating their own practice without carrying the burden of business administration and back office functions. In this capacity our partners can focus on what they do best - providing excellence in patient care! PRN has a fierce commitment to our therapist partners with proven revenue cycle management, personalized human resources, regional business development and contract opportunities. PRN is the most prominent network of independently operated physical & hand rehabilitation centers in the western United States. After starting out in southern California with one practice, PRN presently serves over 120 centers in nine states.